InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a report issued on Tuesday. The firm issued a sell rating on the stock.

Separately, Lake Street Capital began coverage on shares of InspireMD in a research note on Wednesday, December 11th. They issued a “buy” rating and a $5.00 price target on the stock.

InspireMD Stock Performance

Shares of NYSE NSPR opened at $2.89 on Tuesday. The firm has a fifty day moving average of $2.83 and a 200 day moving average of $2.72. The firm has a market cap of $75.38 million, a PE ratio of -3.85 and a beta of 0.99. InspireMD has a one year low of $1.81 and a one year high of $3.42.

InspireMD (NYSE:NSPR) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.04. The firm had revenue of $1.81 million during the quarter, compared to analysts’ expectations of $1.74 million. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. During the same quarter last year, the firm earned ($0.15) earnings per share. On average, equities analysts predict that InspireMD will post -0.79 EPS for the current fiscal year.

Institutional Trading of InspireMD

A hedge fund recently bought a new stake in InspireMD stock. Parkman Healthcare Partners LLC bought a new stake in InspireMD, Inc. (NYSE:NSPR) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 104,081 shares of the company’s stock, valued at approximately $279,000. Parkman Healthcare Partners LLC owned about 0.42% of InspireMD at the end of the most recent quarter. Institutional investors and hedge funds own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.